HEALTHCARE & HEALTHCARE SERVICES

Numinus Wellness, Inc. (TSX: NUMI, OTCQX: NUMIF)

Numinus Stands Tall as Others Fall

Update Note · 21 Mar 2023

Opportunity knocks. In a period of sector upheaval, Numinus remains a steadfast business, with operating profitability in clear line of sight. The company is well positioned to benefit from reduced competition.

HEALTHCARE & HEALTHCARE SERVICES

Shroom Shmooz: Thoughts on Pathways to More Robust Payor Coverage for PAT

Industry Report · 13 Mar 2023

Affordability is an important condition for broad-based accessibility to psychedelic-assisted therapy (PAT), both now (ketamine) and in the future (MDMA, psilocybin, et al.). This makes the evolution of payor coverage as critical a part of the development of PAT as the clinical trial outcomes and...

HEALTHCARE & HEALTHCARE SERVICES

Numinus Wellness, Inc. (TSX: NUMI, OTCQX: NUMIF)

Cedar Clinic Research – An Important Strategic Asset

Management Series · 02 Mar 2023

Water Tower Research hosted Numinus’ Chief Science Officer Dr. Paul Thielking on February 28 for a fireside chat. Dr. Thielking, a former clinician and a certified psychiatrist with extensive experience in the research and development of psychedelic-based interventions for mental health disorders...

HEALTHCARE & HEALTHCARE SERVICES

Numinus Wellness, Inc. (TSX: NUMI, OTCQX: NUMIF)

Fireside Chat: Chief Science Officer Dr. Paul Thielking, February 28, 2023, at 3:00 pm ET

Fireside Chat Invitation · 22 Feb 2023

Please join us for a conversation with Dr. Paul Thielking, Chief Science Officer of Numinus Inc., on Tuesday, February 28, 2023, at 3:00 pm ET.

HEALTHCARE & HEALTHCARE SERVICES

Shroom Shmooz: Controversies Surrounding Psychedelic Patents

Industry Report · 02 Feb 2023

The resurgence of interest in psychedelic science and research, particularly since 2017, reinforced by the mental health consequences of the pandemic, has resulted in a significant pick-up in active clinical trials investigating the therapeutic value of a variety of psychedelics. This, in turn, h...

HEALTHCARE & HEALTHCARE SERVICES

Numinus Wellness, Inc. (TSX: NUMI, OTCQX: NUMIF)

Preparing for a Good Brew

Update Note · 01 Feb 2023

Another milestone for Numinus. Numinus announced today that it has been given the regulatory green light from Health Canada to test the safety and efficacy of whole psilocybe cubensis tea. Psilocybe cubensis is the most well- known type of hundreds of hallucinogenic mushroom species that contain ...

HEALTHCARE & HEALTHCARE SERVICES

Numinus Wellness, Inc. (TSX: NUMI, OTCQX: NUMIF)

Blowout 1QFY23 Results; Profitability in Line of Sight

Update Note · 17 Jan 2023

1QFY23 delivers impressive follow-up results. Numinus’ fiscal first quarter ended November 30, 2022, delivered a strong follow-up to the preceding quarter, which had been robustly affected by a first-time contribution from Novamind. 1QFY23 recorded sequential revenue growth of ~36% to C$5.67 mill...

HEALTHCARE & HEALTHCARE SERVICES

Numinus Wellness, Inc. (TSX: NUMI, OTCQX: NUMIF)

Scaled Up and Readying for Further Growth

Management Series · 14 Dec 2022

Water Tower Research hosted CEO and Founder Payton Nyquvest of Numinus on December 8, 2022. Our discussion focused on the key takes from Numinus’ recently reported 4QFY22 earnings report, expectations going forward, and upcoming catalysts for the company.

HEALTHCARE & HEALTHCARE SERVICES

Shroom Shmooz: Thoughts on the Regulatory Pathway to the Legalization of Psychedelics in North America

Industry Report · 14 Dec 2022

We are initiating a monthly report on the psychedelics sector. Each month, we will focus on a specific topic germane to the space. In this inaugural report, we look at the regulatory landscape for psychedelics and consider possible regulatory pathways to the decriminalization or legalization of p...